AI-PRS Drug Combination Screening for Colorectal Carcinoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating colorectal carcinoma with single drugs face challenges such as drug resistance, leading to reduced efficacy, and the process of screening drug combinations is time-consuming and labor-intensive.
Innovation Solution
A method using an Artificial Intelligence-Phenotypic Response Surface (AI-PRS) platform to quickly screen effective drug combinations from existing clinical drugs, specifically combining Regorafenib, Gemcitabine, Cetuximab, and 5-Fluorouracil, by measuring IC50 values and cell viability, fitting regression functions, and generating a rank table to identify optimal drug combinations for treating colorectal carcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-drug therapy is used for colorectal carcinoma, then treatment simplicity is maintained, but drug resistance develops and efficacy reaches a plateau
Solution Approach 1:
The patent combines multiple existing clinical drugs into specific combinations (e.g., Regorafenib plus Gemcitabine, or Regorafenib plus Gemcitabine plus Cetuximab) to overcome drug resistance and enhance therapeutic efficacy. This merging approach allows the drugs to work synergistically, targeting different pathways in cancer cells simultaneously, thereby preventing resistance development while maintaining treatment simplicity through standardized combination protocols
2Reliability
If drug combination screening is performed using traditional methods, then comprehensive evaluation is achieved, but the process consumes excessive manpower and time
Solution Approach 1:
The patent performs preliminary in vitro screening of drug combinations on colorectal carcinoma cell lines before in vivo testing. This preliminary action identifies promising combinations early, allowing the subsequent in vivo screening to focus only on pre-selected candidates, thereby dramatically reducing the time and resources required for comprehensive evaluation while maintaining screening accuracy
Solution Approach 2:
The screening process is segmented into distinct phases: in vitro cell line screening, in vivo mouse model verification, and clinical application. Each phase screens a progressively smaller set of candidates, dividing the overwhelming task of comprehensive drug combination evaluation into manageable segments that can be completed efficiently at each stage
Data Source
AI summary
A method of screening for a drug combination for treating colorectal carcinoma, the screened drug combination and its related application are provided. The drug combination includes at least three selected from Regorafenib, Gemcitabine, Cetuximab and 5-Fluorouracil. With the method of the disclosure, the best and novel drug combination can be selected from the existing clinical drugs, the technical effect of rapidly screening for a drug combination can be achieved, and the screened combination drug has an excellent therapeutic effect.